https://hstalks.com/category/754/pharmaceutical-sciences/?biosci New and updated series & talks on Pharmaceutical Sciences from HSTalks' Biomedical & Life Sciences Collection. daily 1 2006-01-01T12:00+00:00 Henry Stewart Talks en © Copyright Henry Stewart Talks Ltd. The Biomedical & Life Sciences Collection © Copyright Henry Stewart Talks Ltd. https://hstalks.com/t/25905/preclinical-to-clinical-translation/?biosci Preclinical to clinical translation - Animal model challenges - Biomarker role and validation - PK/PD data integration - Early phase trial design pitfalls - Continual learning and scientific rigor - Collaboration in therapy development Preclinical to clinical translation Preclinical to clinical translation, Animal model challenges, Biomarker role and validation, PK/PD data integration, Early phase trial design pitfalls, Continual learning and scientific rigor, Collaboration in therapy development 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/20023/in-silico-selection/?biosci Molecular modelling benefits - Molecular predictions - Docking studies - Binding affinities - In silico druglikeness prediction - Lipinski's rule of five In silico selection Dr. Wayne Carter Molecular modelling benefits, Molecular predictions, Docking studies, Binding affinities, In silico druglikeness prediction, Lipinski's rule of five 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/25904/drug-development-attrition/?biosci Drug development attrition rates - Causes of attrition - Translational gap preclinical vs human - Costs of drug attrition - Strategies to improve success rates - Advances in oncology therapies - Regulatory challenges and safety Drug development attrition Drug development attrition rates, Causes of attrition, Translational gap preclinical vs human, Costs of drug attrition, Strategies to improve success rates, Advances in oncology therapies, Regulatory challenges and safety 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/25906/early-discovery-candidate-selection/?biosci Candidate Discovery - Screening Cascades & Triage - Drug-likeness Filters - Assessing Potency & Selectivity - Early ADMET Profiling - Decision-Support Tools - Portfolio Prioritization Early discovery candidate selection Candidate Discovery, Screening Cascades & Triage, Drug-likeness Filters, Assessing Potency & Selectivity, Early ADMET Profiling, Decision-Support Tools, Portfolio Prioritization 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/21475/psoriasis-diagnosis-overview/?biosci Clinical identification of psoriasis - Pathogenesis - Classification of psoriasis - Psoriatic arthritis - Enthesitis - Comorbidities in psoriatic disease - Malignancy and psoriasis - Quality of life in psoriasis Psoriasis: diagnosis & overview Dr. Tina Bhutani Clinical identification of psoriasis, Pathogenesis, Classification of psoriasis, Psoriatic arthritis, Enthesitis, Comorbidities in psoriatic disease, Malignancy and psoriasis, Quality of life in psoriasis 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/22201/ich-s5r3-detection-of-reproductive-and-development/?biosci Medicines and pregnancy - Developmental and reproductive toxicity (DART) - Fertility and Early Embryonic Development (FEED) - Embryo-Fetal Development (EFD) - Pre- and Postnatal Development (PPND) - Considerations in pharmaceuticals - Principles of integrated risk assessment ICH S5(R3): detection of reproductive and developmental toxicity for human pharmaceuticals Dr. Günter Waxenecker Medicines and pregnancy, Developmental and reproductive toxicity (DART), Fertility and Early Embryonic Development (FEED), Embryo-Fetal Development (EFD), Pre- and Postnatal Development (PPND), Considerations in pharmaceuticals, Principles of integrated risk assessment 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/25893/drug-formulation-and-delivery-systems/?biosci Drug formulation principles - Dosage forms and routes - Controlled-release technologies - Absorption and bioavailability - Emerging delivery tech (nanotech) - Delivery system pros and cons - Future of drug delivery systems Drug formulation and delivery systems Drug formulation principles, Dosage forms and routes, Controlled-release technologies, Absorption and bioavailability, Emerging delivery tech (nanotech), Delivery system pros and cons, Future of drug delivery systems 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/21937/capillary-gel-electrophoresis-2/?biosci High-performance capillary gel electrophoresis (CGE) - Non-denaturing capillary polyacrylamide gel electrophoresis - Micropreparative capillary gel electrophoresis - SDS-PAGE vs. SDS-CGE - Transitionally cross-linked sieving matrices - Coaxial sheath flow reactor CGE-ESI-MS interface - Techniques used for solubilized and immobilized affinity ligands in CGE Capillary gel electrophoresis 2 Prof. Dr. András Guttman High-performance capillary gel electrophoresis (CGE), Non-denaturing capillary polyacrylamide gel electrophoresis, Micropreparative capillary gel electrophoresis, SDS-PAGE vs. SDS-CGE, Transitionally cross-linked sieving matrices, Coaxial sheath flow reactor CGE-ESI-MS interface, Techniques used for solubilized and immobilized affinity ligands in CGE 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/25907/gono-go-decision-making/?biosci Go/No-Go decision making in pharma R&D - Key criteria: safety, efficacy, PK - Structured risk-benefit analysis and portfolio management - Managing uncertainty and data-driven frameworks - Resource optimization and asset prioritization - Alignment with strategy and patient safety Go/no-go decision making Go/No-Go decision making in pharma R&D, Key criteria: safety, efficacy, PK, Structured risk-benefit analysis and portfolio management, Managing uncertainty and data-driven frameworks, Resource optimization and asset prioritization, Alignment with strategy and patient safety 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/21706/driving-patient-centricity-in-pharmacovigilance-a-/?biosci Patient centricity - Pharmacovigilance - Patient engagement - Risk management - Patient safety - Industry best practices Driving patient centricity in pharmacovigilance: a global to local implementation framework Ms. Farai Moyo Patient centricity, Pharmacovigilance, Patient engagement, Risk management, Patient safety, Industry best practices 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/25903/end-to-end-drug-development-workflow/?biosci Drug development stages - Candidate optimization - Preclinical & clinical testing - Regulatory approval - Post-marketing surveillance - Collaboration & risk management - Precision medicine & AI End-to-end drug development workflow Drug development stages, Candidate optimization, Preclinical & clinical testing, Regulatory approval, Post-marketing surveillance, Collaboration & risk management, Precision medicine & AI 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/25894/pharmacodynamics/?biosci Introduction to Pharmacodynamics - Drug-Receptor Interactions - Dose-Response Relationships - Signal Transduction Mechanisms - Factors Affecting Drug Response - Efficacy vs Safety in Therapy - Types of Drug Effects - Therapeutic Window and Monitoring Pharmacodynamics Introduction to Pharmacodynamics, Drug-Receptor Interactions, Dose-Response Relationships, Signal Transduction Mechanisms, Factors Affecting Drug Response, Efficacy vs Safety in Therapy, Types of Drug Effects, Therapeutic Window and Monitoring 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/17812/drug-discovery-and-development/?biosci Drug design economics - Drug specificity and efficacy - Structure- activity relationships - Drug targets - Drug safety assessment Drug discovery and development Dr. Wayne Carter Drug design economics, Drug specificity and efficacy, Structure- activity relationships, Drug targets, Drug safety assessment 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/22663/drug-safety/?biosci Drug benefits and adverse effects - Mechanism of drug toxicity - Drug metabolism and toxicity - Individual human toxicity - Drug cytotoxicity and genotoxicity - Drug toxicity screening - Teratogenicity Drug safety Dr. Wayne Carter Drug benefits and adverse effects, Mechanism of drug toxicity, Drug metabolism and toxicity, Individual human toxicity, Drug cytotoxicity and genotoxicity, Drug toxicity screening, Teratogenicity 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/21838/current-emerging-therapies-for-the-management-of-p/?biosci Endometrial cancer - Classification of endometrial cancer - Single agent immunotherapy in biomarker selected endometrial cancers - First-line treatment of advanced or recurrent endometrial cancer - Adding PARP inhibition to first line - Adjuvant therapy - Antibody drug conjugates in endometrial cancer - Cell cycle checkpoint inhibitors in endometrial cancers - Hormonal therapy - Biomarker based therapy Current & emerging therapies for the management of patients with endometrial cancer Prof. Brian Slomovitz Endometrial cancer, Classification of endometrial cancer, Single agent immunotherapy in biomarker selected endometrial cancers, First-line treatment of advanced or recurrent endometrial cancer, Adding PARP inhibition to first line, Adjuvant therapy, Antibody drug conjugates in endometrial cancer, Cell cycle checkpoint inhibitors in endometrial cancers, Hormonal therapy, Biomarker based therapy 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/20947/ich-s2-genotoxicity/?biosci ICH S2A & S2B guidelines - Standard battery for genotoxicity testing in S2B - Major revised points of the S2(R1) guideline - In vitro & in vivo genotoxicity tests - Revisions to guidelines ICH S2 genotoxicity Dr. Masamitsu Honma ICH S2A & S2B guidelines, Standard battery for genotoxicity testing in S2B, Major revised points of the S2(R1) guideline, In vitro & in vivo genotoxicity tests, Revisions to guidelines 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/18440/drug-refinement/?biosci Hit and lead - High throughput screening - Lead optimisation - Cycle of drug testing - Drug optimisation and refinement Drug refinement Dr. Wayne Carter Hit and lead, High throughput screening, Lead optimisation, Cycle of drug testing, Drug optimisation and refinement 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/23389/unlocking-a-cryptic-pocket-a-new-approach-to-safer/?biosci CB1 receptor agonists - Cryptic pocket drug design - Molecular dynamics simulations - Peripheral pain therapeutics - Biased GPCR signalling - Tolerance reduction in cannabinoid therapies - Allosteric/sodium binding sites - Translation of analgesic drug candidates (VIP36) to the clinic Unlocking a cryptic pocket: a new approach to safer pain relief Prof. Susruta Majumdar Dr. Vipin Ashok Rangari CB1 receptor agonists, Cryptic pocket drug design, Molecular dynamics simulations, Peripheral pain therapeutics, Biased GPCR signalling, Tolerance reduction in cannabinoid therapies, Allosteric/sodium binding sites, Translation of analgesic drug candidates (VIP36) to the clinic 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection